Menu

Springer Nature Blocks Access to Sensitive Articles Within China

The world’s largest publisher yields to censorship policies of the world’s largest country.

Nov 1, 2017
The Scientist Staff

ISTOCKThe academic publisher Springer Nature has blocked access within China to about 1,000 articles on topics such as the status of Tibet and the 1989 Tiananmen Square protests, the Financial Times reported yesterday (October 31). Although the censorship affects less than 1 percent of the publisher’s material, which can still be read outside China, it is an illustration of how much clout the country’s central government can hold over international companies.

“It’s a symbol of how unprepared we are in the west for China’s influence expanding outwards,” Jonathan Sullivan of the University of Nottingham’s China Policy Institute, tells the Financial Times. “It’s about how we perceive our relationship with China and how much we value principles versus the instrumental benefits of pleasing the authorities in China.”

In a statement to the Associated Press, Springer Nature says that if it had not selectively blocked access to its politically sensitive articles, access to its entire SpringerLink website could have been blocked by China’s “Great Firewall.” If that were to happen, the publisher would join a long list of major international sites that are blocked. Google, for example, was blocked after announcing in 2010 that it would no longer censor its search results within China.

Reuters reports that at least one academic publisher has responded to pressure to move away from censorship: Cambridge University Press recently reversed a decision to remove about 300 articles from its Chinese site, after it was criticized by academics “as an affront to academic freedom.”

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.